Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQQD6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $87,456
Award facts
- Contract value 100% obligated
- $87,455.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $87,455.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. This firm fixed-price delivery order, issued on January 30, 2026, with an ultimate completion date of February 23, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support the Department of Defense's pharmaceutical supply requirements.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program (contract SPE2DR) valued at $499.999 billion with a completion date of December 31, 2036, positioning the company as a critical regional prime vendor contractor for military healthcare facilities worldwide. The company's extensive product portfolio encompasses oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with this delivery order for Keytruda—a oncology treatment—reflecting its established capability to fulfill specialized pharmaceutical requirements across the federal military medical system. The contractor has demonstrated substantial federal contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FQQD6?
SPE2DR26FQQD6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FQQD6 worth?
The government has obligated $87,456 on SPE2DR26FQQD6.
Is contract SPE2DR26FQQD6 an order under another contract?
Yes. SPE2DR26FQQD6 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQD6 competed?
The extent of competition for SPE2DR26FQQD6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award